tbuckley/cabot-search huggingface dataset:
Financial toxicity in hematological malignancies: a systematic review
Authors: Evguenia Ouchveridze, Rahul Banerjee, Aakash Desai, Muhammad Aziz, Wade Lee-Smith, Hira Mian, Katherine Berger, Brian McClune, Douglas Sborov, Muzaffar Qazilbash, Shaji Kumar, Ghulam Rehman Mohyuddin
Journal: Blood Cancer Journal (2022)

Hematologic malignancy outcomes have remarkably improved in the past decade with further advancement expected in future years. However, the detrimental effects of financial toxicity (FT) on patients with hematologic malignancies, because of both diagnoses and subsequent treatments, have not been studied comprehensively. We performed a systematic review of all studies reporting FT as a primary or secondary outcome among adult or pediatric patients with hematological malignancies. A total of 55 studies met the inclusion criteria for analysis. Across studies, 20-50% of patients reported some form of FT, including loss of work productivity, food and transportation costs, and depletion of savings. Younger age, lower-income level, unemployment, and rural residence were the most commonly identified risk factors for FT. Two studies looked at survival outcomes, with one reporting improvement in survival with a decrease in financial toxicity. However, significant heterogeneity in FT definitions was found between countries and payor systems. Only half of the studies (51%, n = 28) used validated survey instruments such as the COST assessment. The present systematic review identified that FT is common in patients with hematological malignancies and may be associated with poorer outcomes. However, studies of FT generally use non-standardized methods with cross-sectional analyses rather than longitudinal, prospective assessments. Further work is needed to standardize FT reporting and investigate measures to alleviate FT among patients with hematologic malignancies.
Alterations in 18F-FDG PET/MRI and 15O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination: A Pilot Study: Reply
Authors: Dheeratama Siripongsatian, Chanisa Chotipanich
Journal: Clinical Nuclear Medicine (2022)

National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand [email protected] Conflicts of interest and sources of funding: none declared.
Nutrition perceptions, needs and practices among patients with plasma cell disorders
Authors: Maria A. Malik, Nathan W. Sweeney, Mohammad Jafri, Andriy Derkach, Cynthia Chmielewski, Peter A. Adintori, Sham Mailankody, Neha Korde, Carlyn R. Tan, Hani Hassoun, Malin Hultcrantz, Jens Hillengass, Susan E. McCann, Neil Iyengar, Saad Usmani, Sergio A. Giralt, Ola Landgren, Marcel R. M. van den Brink, Jennifer M. Ahlstrom, Alexander M. Lesokhin, Anita D’Souza, Susan Chimonas, Urvi A. Shah
Journal: Blood Cancer Journal (2022)
Corrigendum to ‘128P Surgical management of lung metastases: A work-in-progress report from an international ESTS research group’ Annals of Oncology Volume 33 Supplement 2 (2022) S91-S92
Authors: E. Prisciandaro, L. Bertolaccini, D. van Raemdonck, J. Moons, P. De Leyn, H. Decaluwé, L. Spaggiari, L.J. Ceulemans
Journal: Annals of Oncology (2022)
TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche
Authors: Juo-Chin Yao, Karolyn A. Oetjen, Tianjiao Wang, Haoliang Xu, Grazia Abou-Ezzi, Joseph R. Krambs, Salil Uttarwar, Eric J. Duncavage, Daniel C. Link
Journal: Journal of Clinical Investigation (2022)

Myeloproliferative neoplasms (MPNs) are associated with significant alterations in the bone marrow microenvironment that include decreased expression of key niche factors and myelofibrosis. Here, we explored the contribution of TGF-β to these alterations by abrogating TGF-β signaling in bone marrow mesenchymal stromal cells. Loss of TGF-β signaling in Osx-Cre–targeted MSCs prevented the development of myelofibrosis in both MPLW515L and Jak2V617F models of MPNs. In contrast, despite the absence of myelofibrosis, loss of TGF-β signaling in mesenchymal stromal cells did not rescue the defective hematopoietic niche induced by MPLW515L, as evidenced by decreased bone marrow cellularity, hematopoietic stem/progenitor cell number, and Cxcl12 and Kitlg expression, and the presence of splenic extramedullary hematopoiesis. Induction of myelofibrosis by MPLW515L was intact in Osx-Cre Smad4fl/fl recipients, demonstrating that SMAD4-independent TGF-β signaling mediates the myelofibrosis phenotype. Indeed, treatment with a c-Jun N-terminal kinase (JNK) inhibitor prevented the development of myelofibrosis induced by MPLW515L. Together, these data show that JNK-dependent TGF-β signaling in mesenchymal stromal cells is responsible for the development of myelofibrosis but not hematopoietic niche disruption in MPNs, suggesting that the signals that regulate niche gene expression in bone marrow mesenchymal stromal cells are distinct from those that induce a fibrogenic program.
FDG PET/CT Imaging Findings of Renal Infarction in a Patient With Gastric Adenocarcinoma
Authors: Ebru Tatci, Ozlem Ozmen, Atila Gökçek
Journal: Clinical Nuclear Medicine (2022)

We report the FDG PET/CT findings of renal infarction in a 75-year-old woman patient who received chemotherapy for gastric adenocarcinoma. The patient was referred to our hospital for the evaluation of her response to chemotherapy. PET/CT detected circumferential increased FDG uptake in the outer part of the left renal cortex. The remaining of the renal cortex was photopenic. Abdominal CT angiography showed no contrast enhancement within the renal parenchyma. There was no contrast enhancement in the lumen of the left renal artery. These findings were thought to be consistent with the left renal infarct due to the occlusion of the left renal artery.
Acute Kidney Injury and the Field of Dreams—If We Predict It, Maybe They’ll Come
Authors: John A. Kellum, Faisal G. Bakaeen, Danny Chu
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Association of COVID-19 Vaccination During Early Pregnancy With Risk of Congenital Fetal Anomalies
Authors: Rachel S. Ruderman, Jessica Mormol, Emma Trawick, Madeline F. Perry, Emma C. Allen, Danielle Millan, Emily S. Miller
Journal: JAMA Pediatrics (2022)

Discussion | An intervention consisting of SRH plus PN guidance and follow-up to address family social needs was associated with a reduction in the instantaneous probability of child hospitalization through 90 days after intervention compared with SRH alone after adjusting for covariates.We believe this finding adds to the emerging evidence base of how social interventions can lead to better health and health care outcomes. 5,6lthough the hazard ratio comparing intervention groups was not significant at 1 year of follow-up, it was significant at 90 days, suggesting stronger proximal intervention effects.These findings differ from previous study of the effects of PNs on hospitalization at 1 year 5 and suggest that retaining utilization benefits may require ongoing supports beyond 90 days to continually prevent hospitalization.Similar to previous work, 5 this study found no associations with ED use, perhaps because the interventions were equally protective against ED-manageable illness.Future studies should explore differential intervention effects on inpatient and ED use.Previous analyses 4 did not detect between-group differences in social needs or health outcomes in this trial.Possible explanations include differences in follow-up timing and methodologies (time to event vs single time point analysis), and a range of mechanisms may mediate intervention effects.This study has several limitations.It was conducted at 1 clinic and thus may have underestimated or undermeasured utilization by collecting data from only 1 health system.Furthermore, we lacked a comprehensive child medical complexity indicator and had no ability to measure effects compared with a true control group that did not receive any intervention.In this study, providing a social resources handout with PN support vs a social resources handout alone was associated with a decreased instantaneous probability of hospitalization over a 90-day follow-up period.As health care systems increasingly turn to social care strategies to improve health and utilization patterns, more research is needed on the effectiveness of different interventions.
The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis
Authors: Maria Krutikov, Lena Faust, Vladyslav Nikolayevskyy, Yohhei Hamada, Rishi K Gupta, Daniela Cirillo, Alberto Matteelli, Alexei Korobitsyn, Claudia M Denkinger, Molebogeng X Rangaka
Journal: The Lancet Infectious Diseases (2021)
Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes
Authors: Anna Gardiner, John Kidd, Maria C Elias, Kayla Young, Brent Mabey, Nassim Taherian, Shelly Cummings, Mokenge Malafa, Eric Rosenthal, Jennifer B Permuth
Journal: JNCI Journal of the National Cancer Institute (2022)

Although several hereditary cancer predisposition genes have been implicated in pancreatic ductal adenocarcinoma (PDAC) susceptibility, gene-specific risks are not well defined and are potentially biased because of the design of previous studies. More precise and unbiased risk estimates can result in screening and prevention better tailored to genetic findings.
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
Authors: Yanchen Zhou, Hweixian L Penny, Mark A Kroenke, Bianca Bautista, Kelly Hainline, Lynette S Chea, Jane Parnes, Daniel T Mytych
Journal: Journal for ImmunoTherapy of Cancer (2022)

With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering the clinic, recent data highlight immunogenicity as an emerging challenge in the development of such novel biologics. This review focuses on the immunogenicity risk assessment (IgRA) of BsAb-based immunotherapies for cancer, highlighting several risk factors that need to be considered. These include the novel scaffolds consisting of bioengineered sequences, the potentially synergistic immunomodulating mechanisms of action (MOAs) from different domains of the BsAb, as well as several other product-related and patient-related factors. In addition, the clinical relevance of anti-drug antibodies (ADAs) against selected BsAbs developed as anticancer agents is reviewed and the advances in our knowledge of tools and strategies for immunogenicity prediction, monitoring, and mitigation are discussed. It is critical to implement a drug-specific IgRA during the early development stage to guide ADA monitoring and risk management strategies. This IgRA may include a combination of several assessment tools to identify drug-specific risks as well as a proactive risk mitigation approach for candidate or format selection during the preclinical stage. The IgRA is an on-going process throughout clinical development. IgRA during the clinical stage may bridge the gap between preclinical immunogenicity prediction and clinical immunogenicity, and retrospectively guide optimization efforts for next-generation BsAbs. This iterative process throughout development may improve the reliability of the IgRA and enable the implementation of effective risk mitigation strategies, laying the foundation for improved clinical success.
FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression
Authors: Sai Wang, Rilu Feng, Shan Shan Wang, Hui Liu, Chen Shao, Yujia Li, Frederik Link, Stefan Munker, Roman Liebe, Christoph Meyer, Elke Burgermeister, Matthias Ebert, Steven Dooley, Huiguo Ding, Honglei Weng
Journal: Gut (2022)

Multidrug resistance protein 2 (MRP2) is a bottleneck in bilirubin excretion. Its loss is sufficient to induce hyperbilirubinaemia, a prevailing characteristic of acute liver failure (ALF) that is closely associated with clinical outcome. This study scrutinises the transcriptional regulation of MRP2 under different pathophysiological conditions.Hepatic MRP2, farnesoid X receptor (FXR) and Forkhead box A2 (FOXA2) expression and clinicopathologic associations were examined by immunohistochemistry in 14 patients with cirrhosis and 22 patients with ALF. MRP2 regulatory mechanisms were investigated in primary hepatocytes, Fxr-/- mice and lipopolysaccharide (LPS)-treated mice.Physiologically, homeostatic MRP2 transcription is mediated by the nuclear receptor FXR/retinoid X receptor complex. Fxr-/- mice lack apical MRP2 expression and rapidly progress into hyperbilirubinaemia. In patients with ALF, hepatic FXR expression is undetectable, however, patients without infection maintain apical MRP2 expression and do not suffer from hyperbilirubinaemia. These patients express FOXA2 in hepatocytes. FOXA2 upregulates MRP2 transcription through binding to its promoter. Physiologically, nuclear FOXA2 translocation is inhibited by insulin. In ALF, high levels of glucagon and tumour necrosis factor α induce FOXA2 expression and nuclear translocation in hepatocytes. Impressively, ALF patients with sepsis express low levels of FOXA2, lose MRP2 expression and develop severe hyperbilirubinaemia. In this case, LPS inhibits FXR expression, induces FOXA2 nuclear exclusion and thus abrogates the compensatory MRP2 upregulation. In both Fxr-/- and LPS-treated mice, ectopic FOXA2 expression restored apical MRP2 expression and normalised serum bilirubin levels.FOXA2 replaces FXR to maintain MRP2 expression in ALF without sepsis. Ectopic FOXA2 expression to maintain MRP2 represents a potential strategy to prevent hyperbilirubinaemia in septic ALF.
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in Dermatofibrosarcoma Protuberans
Authors: Junhao Wu, Shumao Zhang, Zijuan Rao, Yingwei Wang, Chunyin Zhang
Journal: Clinical Nuclear Medicine (2022)

Dermatofibrosarcoma protuberans is a rare soft tissue sarcoma with a high recurrence rate. Herein, we present 68Ga-FAPI and 18F-FDG PET/CT findings of dermatofibrosarcoma protuberans in a 45-year-old man. Dermatofibrosarcoma protuberans only shows limited FDG uptakes on 18F-FDG PET/CT, but demonstrated intense tracer uptakes on 68Ga-FAPI PET/CT. In this case, 68Ga-FAPI was superior to 18F-FDG PET/CT in detecting dermatofibrosarcoma protuberans.
Association of the 2020 US Presidential Election With Hospitalizations for Acute Cardiovascular Conditions
Authors: Matthew T. Mefford, Jamal S. Rana, Kristi Reynolds, Omesh Ranasinghe, Murray A. Mittleman, Jennifer Y. Liu, Lei Qian, Hui Zhou, Teresa N. Harrison, Alan C. Geller, Richard P. Sloan, Elizabeth Mostofsky, David R. Williams, Stephen Sidney
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Prior studies found a higher risk of acute cardiovascular disease (CVD) around population-wide psychosocial or environmental stressors. Less is known about acute CVD risk in relation to political events. <h3>Objective</h3> To examine acute CVD hospitalizations following the 2020 presidential election. <h3>Design, Setting, and Participants</h3> This retrospective cohort study examined acute CVD hospitalizations following the 2020 presidential election. Participants were adult members aged 18 years or older at Kaiser Permanente Southern California and Kaiser Permanente Northern California, 2 large, integrated health care delivery systems. Statistical analysis was performed from March to July 2021. <h3>Exposure</h3> 2020 US presidential election. <h3>Main Outcomes and Measures</h3> Hospitalizations for acute CVD around the 2020 presidential election were examined. CVD was defined as hospitalizations for acute myocardial infarction (AMI), heart failure (HF), or stroke. Rate ratios (RR) and 95% CIs were calculated comparing rates of CVD hospitalization in the 5 days following the 2020 election with the same 5-day period 2 weeks prior. <h3>Results</h3> Among 6 396 830 adults (3 970 077 [62.1%] aged 18 to 54 years; 3 422 479 [53.5%] female; 1 083 128 [16.9%] Asian/Pacific Islander, 2 101 367 [32.9%] Hispanic, and 2 641 897 [41.3%] White), rates of hospitalization for CVD following the election (666 hospitalizations; rate = 760.5 per 100 000 person-years [PY]) were 1.17 times higher (95% CI, 1.05-1.31) compared with the same 5-day period 2 weeks prior (569 hospitalizations; rate = 648.0 per 100 000 PY). Rates of AMI were significantly higher following the election (RR, 1.42; 95% CI, 1.13-1.79). No significant difference was found for stroke (RR, 1.02; 95% CI, 0.86-1.21) or HF (RR, 1.18; 95% CI, 0.98-1.42). <h3>Conclusions and Relevance</h3> Higher rates of acute CVD hospitalization were observed following the 2020 presidential election. Awareness of the heightened risk of CVD and strategies to mitigate risk during notable political events are needed.
Preventing disease progression in multiple sclerosis—insights from large real-world cohorts
Authors: Sinah Engel, Frauke Zipp
Journal: Genome Medicine (2022)

Abstract Multiple sclerosis is a chronic neuroinflammatory disease with a highly heterogeneous disease course. Preventing lasting disability requires early identification of persons at risk and novel approaches towards patient stratification for personalized treatment decisions. In this comment, we discuss the importance of large datasets of real-world cohorts in order to address this unmet need.
Reply to Lv and Yang
Authors: Motohiko Kato, Yoji Takeuchi, Shu Hoteya, Tsuneo Oyama, Satoru Nonaka, Shoichi Yoshimizu, Naomi Kakushima, Ken Ohata, Hironori Yamamoto, Yuko Hara, Hisashi Doyama, Osamu Dohi, Yasushi Yamasaki, Hiroya Ueyama, Kengo Takimoto, Koichi Kurahara, Tomoaki Tashima, Nobutsugu Abe, Atsushi Nakayama, Ichiro Oda, Naohisa Yahagi
Journal: Endoscopy (2022)

See also: Missed lesions and artificial intelligence during colonoscopy: the tireless working expert in the roomEndoscopy 2022; 54(05): 473-474DOI: 10.1055/a-1669-8814
A secondary metabolite drives intraspecies antagonism in a gut symbiont that is inhibited by cell-wall acetylation
Authors: Mustafa Özçam, Jee-Hwan Oh, Restituto Tocmo, Deepa Acharya, Shenwei Zhang, Theresa J. Astmann, Mark Heggen, Silvette Ruiz-Ramírez, Fuyong Li, Christopher C. Cheng, Eugenio Vivas, Federico E. Rey, Jan Claesen, Tim S. Bugni, Jens Walter, Jan-Peter van Pijkeren
Journal: Cell Host & Microbe (2022)

The mammalian microbiome encodes numerous secondary metabolite biosynthetic gene clusters; yet, their role in microbe-microbe interactions is unclear. Here, we characterized two polyketide synthase gene clusters (fun and pks) in the gut symbiont Limosilactobacillus reuteri. The pks, but not the fun, cluster encodes antimicrobial activity. Forty-one of 51 L. reuteri strains tested are sensitive to Pks products; this finding was independent of strains' host origin. Sensitivity to Pks was also established in intraspecies competition experiments in gnotobiotic mice. Comparative genome analyses between Pks-resistant and -sensitive strains identified an acyltransferase gene (act) unique to Pks-resistant strains. Subsequent cell-wall analysis of wild-type and act mutant strains showed that Act acetylates cell-wall components, providing resistance to Pks-mediated killing. Additionally, pks mutants lost their competitive advantage, while act mutants lost their Pks resistance in in vivo competition assays. These findings provide insight into how closely related gut symbionts can compete and co-exist in the gastrointestinal tract.
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Authors: Pavlos Msaouel, Sangeeta Goswami, Peter F. Thall, Xuemei Wang, Ying Yuan, Eric Jonasch, Jianjun Gao, Matthew T. Campbell, Amishi Yogesh Shah, Paul Gettys Corn, Alda L. Tam, Kamran Ahrar, Priya Rao, Kanishka Sircar, Lorenzo Cohen, Sreyashi Basu, Fei Duan, Sonali Jindal, Yuwei Zhang, Hong Chen, Shalini S. Yadav, Ronald Shazer, Hirak Der-Torossian, James P. Allison, Padmanee Sharma, Nizar M. Tannir
Journal: Science Translational Medicine (2022)

The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses to anti–PD-1 therapy by modulating immune-suppressive myeloid cells. We conducted a phase 1-2 trial to choose an optimal sitravatinib dose combined with a fixed dose of nivolumab in 42 immunotherapy-naïve patients with ccRCC refractory to prior antiangiogenic therapies. The combination demonstrated no unexpected toxicities and achieved an objective response rate of 35.7% and a median progression-free survival of 11.7 months, with 80.1% of patients alive after a median follow-up of 18.7 months. Baseline peripheral blood neutrophil-to-lymphocyte ratio correlated with response to sitravatinib and nivolumab. Patients with liver metastases showed durable responses comparable to patients without liver metastases. In addition, correlative studies demonstrated reduction of immune-suppressive myeloid cells in the periphery and tumor microenvironment following sitravatinib treatment. This study provides a rationally designed combinatorial strategy to improve outcomes of anti–PD-1 therapy in advanced ccRCC.
Communicating the Benefits of Vaccination in Light of Potential Risks
Authors: Ann Marie Navar, Robert O. Bonow
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal